Introduction
============

Hereditary mutations in a variety of genes involved in double-strand break (DSB) repair are associated with an increased risk of developing female breast cancer.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ However, only a fraction of approximately 30% of this hereditary cancer risk is explained by currently known high-penetrance susceptibility genes. A large portion of the remaining predisposition to breast cancer may be explained by a polygenic model involving a combination of multiple genomic risk factors, including the effect of low-penetrance susceptibility alleles. These include polymorphisms in genes involved in several metabolic pathways, signal transduction and DNA repair.^[@bib7]^

In the Finnish population, *PALB2* was reported to represent the most notable breast cancer susceptibility gene^[@bib8]^ along with the previously identified *BRCA1* and *BRCA2* genes. Interestingly, there is only one single aberration in *PALB2* described in this population so far, namely the relatively common c.1592delT protein truncation founder mutation. In females, this mutation leads to a sixfold increase of the breast cancer risk^[@bib9]^ and occurs in 0.2% of the general population.^[@bib10]^ Several investigations have now shown that monoallelic mutations in *PALB2* increase the risk of developing female breast cancer,^[@bib8],\ [@bib11],\ [@bib12]^ whereas biallelic mutations cause *Fanconi anemia* (FA) of subtype FA-N.^[@bib13],\ [@bib14],\ [@bib15]^ A hallmark of FA patient cells is defectiveness in interstrand crosslink repair, a feature that is being made use of in diagnostic patient classification.^[@bib16]^

DNA strand breaks, particularly DSBs, are the most lethal genomic lesions. In mammalian cells, DSBs are repaired by two main pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR).^[@bib17]^ DSBs generated during crosslink repair are normally subject to HR repair.^[@bib16],\ [@bib18]^ HR starts with processing of the DNA end, thereby forming single-stranded DNA (ssDNA) 3\'ends, which are quickly covered by the human ssDNA-binding protein RPA. DNA end processing involves the MRE11-RAD50-Nibrin and BRCA1-CtIP complexes. PALB2 acts as the mediator between BRCA1 and BRCA2 via independent interactions at its N- and C-terminus, respectively.^[@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ The C-terminus additionally binds RAD51C, another breast/ovarian cancer susceptibility as well as FA gene product, thus forming a HR complex also containing XRCC3 and RAD51.^[@bib23]^ BRCA1 may concentrate PALB2 at DNA damage sites in chromatin,^[@bib20],\ [@bib21]^ where PALB2 recruits and permits stable localization of BRCA2 to these focal intranuclear sites.^[@bib19],\ [@bib24],\ [@bib25]^ BRCA2 promotes the assembly of RAD51 into nucleoprotein filaments thereby replacing RPA.^[@bib26],\ [@bib27]^ RAD51 nucleoprotein filaments invade the sister chromatid in search for homology. This represents the central step of HR. It either starts repair synthesis during the unilateral exchange process called synthesis-dependent strand annealing or formation of double Holliday Junctions, which are later resolved in a crossover or non-crossover manner during canonical HR.^[@bib17]^ PALB2 has also been reported to bind to ssDNA where it interacts with RAD51 to stimulate strand invasion.^[@bib28]^ Importantly, similar HR-related processes that require PALB2, BRCA2 and RAD51 have also a central role in the reactivation of stalled replication forks.^[@bib29],\ [@bib30],\ [@bib31],\ [@bib32],\ [@bib33]^ Altogether, PALB2 has been described to exhibit indirect and direct functions in RAD51-dependent HR, which is considered to be the most accurate DSB repair pathway. High fidelity repair by HR requires perfect homologies between the donor and the acceptor sequence, which is why it takes place in the S/G2-phase, when identical sister chromatids are available.^[@bib34]^ For comparison, NHEJ, in particular the alternative microhomology-mediated end-joining (MMEJ) sub-pathway, and an alternative RAD51-independent homologous DSB repair pathway, namely single-strand annealing (SSA), are error-prone DSB repair mechanisms that are not limited to a particular cell cycle phase.^[@bib34],\ [@bib35]^ NHEJ can result in the loss or gain of nucleotides and hence in the disruption of genomic integrity. Similarly, SSA starts with DNA end processing, however, followed by DNA annealing between genomic repeat sequences with extensive homologies. SSA always leads to the loss of the intervening DNA sequences and, therefore, is considered mutagenic.^[@bib35]^

In a previous study, we observed enhanced error-prone DSB repair activities, namely MMEJ and SSA, in lymphoblastoid cell lines (LCLs) from *BRCA1* and *BRCA2* mutation carriers, respectively.^[@bib36]^ As PALB2 was discovered to physically connect BRCA1 and BRCA2,^[@bib19],\ [@bib20],\ [@bib21]^ we mechanistically dissected DSB repair activities in LCLs derived from female individuals heterozygous for the Finnish *PALB2* c.1592delT founder mutation. The breast cancer risks associated with *PALB2* mutations have been reported to synergize with additional genetic factors.^[@bib37],\ [@bib38]^ To better understand the impact of polygenic interactions with the Finnish founder mutation on cancer risk-associated DSB repair dysfunction, we compared cohorts with and without *PALB2* c.1592delT mutation and with and without breast cancer. The data presented in this study demonstrate that mutated *PALB2* derepresses SSA and MMEJ, a phenotype which very likely cooperates with additional changes in carrier individuals with cancer, such as deregulation of 53BP1 levels associated with the lack of protection against excessive end processing.

Results
=======

Individuals heterozygous for the Finnish *PALB2* founder mutation show specific changes in DSB repair pathway usage
-------------------------------------------------------------------------------------------------------------------

To determine whether and how DSB repair is altered in individuals heterozygous for the Finnish c.1592delT *PALB2* founder mutation, we introduced different *EGFP*-based reporter constructs into LCLs from *PALB2* mutation carriers and healthy individuals with wild-type *PALB2*^[@bib32],\ [@bib39]^ ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Our systematic analysis of pathway-specific DSB repair activities addressed NHEJ, MMEJ, SSA, SSA+HR and HR ([Figures 1a and b](#fig1){ref-type="fig"} and representative FACS plots in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), where *PALB2* wild-type LCL BR-0968 served as internal reference. As summarized in [Table 1](#tbl1){ref-type="table"}, we observed statistically significant increases in NHEJ (1.5- to 3.4-fold), MMEJ (1.8- to 9.6-fold), SSA (1.6- to 7.9-fold) and/or SSA+HR (1.8- to 10.9-fold) in five LCLs from *PALB2* mutation carriers, encompassing individuals without (healthy) and with breast cancer (brca). However, in LCL BR-0970 from a breast cancer patient undergoing cytostatic therapy (brca+therapy), no such increases were observed, rather a reduction such as for SSA+HR (to 70%). As the only other exception, significant downregulation of SSA (to 60%) was found in LCL BR-0724 (brca). Regarding HR, we obtained no statistically significant changes in *PALB2*-mutated LCLs, except for BR-0970 (brca+therapy) displaying HR downregulation to 20%. Notably, BR-0970 cells from the breast cancer patient undergoing therapy were the only ones that did not match any of the DSB repair changes observed with the other LCLs from *PALB2* mutation carriers and were therefore excluded from any cohort analysis in this work. Accordingly, augmentation of NHEJ, MMEJ, SSA and SSA+HR was detected in 83% (5/6) of *PALB2*-mutated LCLs. In conclusion, DSB repair analysis of individual LCLs revealed a shift to error-prone DSB repair pathways in *PALB2* mutation carriers with and without breast cancer before therapy.

To take the possibility into account that the internal reference BR-0968 may not perfectly represent the wild-type phenotype, we performed cohort analysis for the informative pathways NHEJ, MMEJ, SSA and SSA+HR. Thus, we calculated mean values of specific DSB repair activities from six *PALB2*-mutated LCLs (excluding BR-0970 from the patient undergoing therapy) and six matched LCLs with wild-type *PALB2* (for individual analysis of LCLs see [Table 1](#tbl1){ref-type="table"}). When comparing the two different genotypes, no statistically significant change in NHEJ was observed. However, the mutation carriers showed a 1.8-fold increase in MMEJ (*P*=0.022) and SSA (*P*=0.001) and a 1.9-fold increase in SSA+HR (*P*=0.002) in relation to the wild-type cohort ([Figure 2a](#fig2){ref-type="fig"}, left panel). Moreover, plotting MMEJ changes in *PALB2*-mutated LCLs ([Table 1](#tbl1){ref-type="table"}) against the respective PALB2 protein levels according to our previous study^[@bib32]^ revealed a statistically significant inverse correlation (*P*=0.0167; Spearman r, two-tailed). When subdividing the group of *PALB2*-mutated LCLs, we noticed a statistically significant 2.0-fold NHEJ increase in the breast cancer patients compared with healthy *PALB2*-mutated donors (*P*=0.005) ([Figure 2a](#fig2){ref-type="fig"}, right panel). No statistically significant MMEJ differences were observed between the subgroups. Furthermore, the breast cancer patients showed a 2.2-fold increase in SSA (*P*=0.0034) and a 2.0-fold increase in SSA+HR (*P*=0.003) compared with the wild-type LCLs. Under the transient assay conditions applied to patient cells, analysis of SSA+HR was previously found to primarily reflect SSA activities, so that the SSA+HR data further supported increased usage of this pathway.^[@bib40],\ [@bib41]^ In summary, cohort analysis confirmed MMEJ and SSA upregulation in *PALB2* c.1592delT mutation carriers versus wild-type controls. When subdividing the group of mutation carriers into healthy and breast cancer-affected individuals, we found a difference only for NHEJ, namely a rise in those with breast cancer. The same subgroup also showed elevated SSA versus the wild-type cohort (not healthy mutation carriers versus the wild-type cohort). Surprisingly, overexpression of wild-type PALB2 did not affect SSA+HR in carriers or wild-type control LCLs ([Figure 2b](#fig2){ref-type="fig"}). Instead overexpression of the truncated PALB2 encoded by *PALB2* c.1592delT caused a 1.6- and 1.5-fold increase in SSA+HR (*P*\<0.0001).

Heterozygously mutated *PALB2* rarely associates with sensitivity to PARP inhibitor treatment
---------------------------------------------------------------------------------------------

Following the detection of ssDNA breaks, poly(ADP-ribosyl)transferase (PARP)1--3 activate various DNA repair pathways and stabilize stalled replication forks.^[@bib42]^ Resolution of stalled forks requires HR, that is, the pathway PALB2 is thought to have a role in.^[@bib32]^ PARP inhibition was shown to eliminate *BRCA1*- and *BRCA2*-mutated tumor cells in preclinical and clinical studies.^[@bib43]^ As PALB2 physically and functionally interacts with BRCA1 and BRCA2,^[@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ sensitivity to PARP inhibition was assessed in the *PALB2*-mutated LCLs. For this purpose, LCLs were treated with different concentrations of the PARP inhibitor 1,5-isoquinolinediol and subjected to MTT assay. As a proof-of-principle, we showed that this approach may detect HR dysfunction in a gene dose-dependent manner, because LCL cells with biallelic *BRCA2* mutation (GM13023A) showed 3.8-fold higher sensitivity (*P*=0.0138) than heterozygously *BRCA2*-mutated (HA238) cells, that is, highest sensitivity compared with wild-type control cells (TK6) ([Table 2](#tbl2){ref-type="table"}). When analyzing *PALB2-*mutated LCLs, we observed statistically significantly reduced IC50 values for BR-0760 (brca) and BR-0970 (brca+therapy) versus the wild-type reference BR-0968. But none of the other five *PALB2*-mutated LCLs showed a significant increase of PARP inhibitor sensitivity. IC50 values of five additional LCLs with wild-type *PALB2* were also not significantly different from the wild-type reference BR-0968. Consistently, cohort analysis of LCLs from wild-type *PALB2* and *PALB2*-mutated donors with or without breast cancer revealed no differences between the mean IC50 values of the subgroups ([Figure 3](#fig3){ref-type="fig"}).

Analysis of DSB repair components reveals accumulation of 53BP1 in healthy *PALB2* mutation carriers
----------------------------------------------------------------------------------------------------

To further delineate the molecular defect caused by heterozygous *PALB2* mutation in DSB repair, we performed immunofluorescence microscopic analysis of nuclear structures indicative of the accumulation and/or removal of DSBs (53BP1) and the assembly/disassembly of the HR repair machinery (RAD51).^[@bib41]^ Depending on the selected genotoxic treatment, distinct DNA repair pathways can be addressed such as canonical NHEJ in the early repair phase after irradiation, HR after treatment with the crosslinker Mitomycin C (MMC).^[@bib16],\ [@bib18],\ [@bib34]^

First, we induced DSBs in LCLs by exposure to ionizing radiation (2 Gy γ-ray) and subjected the cells to immunostaining and quantitative immunofluorescence microscopy at different time points post irradiation. Accumulation of 53BP1 0.5--1 h after ionizing radiation was followed by a gradual decrease of foci numbers indicating DSB formation and subsequent repair both in wild-type and *PALB2*-mutated LCLs ([Supplementary Figure 2a](#sup1){ref-type="supplementary-material"}). When monitoring RAD51 filament assembly post irradiation, we detected similar kinetics of foci accumulation and decline as with 53BP1 ([Supplementary Figure 2b](#sup1){ref-type="supplementary-material"}). A statistically significant difference in 53BP1 or RAD51 foci numbers specific for a *PALB2*--mutated LCL versus the wild-type reference BR-0968 was only observed in one single case each ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"} and further data not shown). To focus on HR, we treated the LCLs with MMC inducing a gradual increase of 53BP1 foci numbers up to 6 h after exposure indicating DSB formation during crosslink processing.^[@bib41]^ MMC treatment did not unveil any difference in 53BP1 accumulation in individual LCLs ([Supplementary Figure 2c](#sup1){ref-type="supplementary-material"}). RPA coats ssDNA and becomes phosphorylated at the 32 kDa subunit (P-RPA) when accumulating on DNA.^[@bib44]^ P-RPA foci kinetics post ionizing radiation did not reveal differences between LCLs from family I members with wild-type or mutated *PALB2* ([Supplementary Figure 2d](#sup1){ref-type="supplementary-material"}). Cohort analysis of LCLs from wild-type and *PALB2*-mutated donors with or without breast cancer verified the increases in foci numbers for both treatment modalities and time points post treatment ([Figure 4](#fig4){ref-type="fig"}). It further demonstrated complete absence of significant differences between the subgroups (wild-type, *PALB2*-mutated and healthy, *PALB2*-mutated and breast cancer) regarding 53BP1 and RAD51 foci/nucleus before and after irradiation as well as 53BP1 foci/nucleus before and after MMC treatment. When recalculating foci data regarding the percentage of responding cells (53BP1: ⩾5 foci/nucleus, RAD51: ⩾2 foci/nucleus), no statistically significant differences were observed except for a small, namely 7% decrease (*P*=0.0302) of 53BP1-positive cells 6 h post-MMC in the breast cancer patients with mutated *PALB2* versus wild-type *PALB2* controls.

In another approach to unravel the molecular components involved in the DSB repair pathway shift in *PALB2*--mutated individuals, we used western blotting to quantify the phosphorylated repair components indicating DNA damage and repair intermediates, respectively. The damage marker γH2AX detects different types of lesions including stalled replication forks,^[@bib45]^ which accumulate after MMC treatment. P-RPA represents a marker of DSB end processing.^[@bib44]^ We performed at least two independent immunoblotting experiments for each of the LCLs from Finnish donors, normalized antigen-specific signals with the loading control and the internal wild-type reference BR-0968 each, and compared values for the wild-type cohort versus *PALB2*-mutated healthy individuals and breast cancer patients ([Figure 5](#fig5){ref-type="fig"}, western blots for individual LCLs in [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

Regarding γH2AX, we observed a trend towards decreased signals in untreated LCLs from mutation carriers with breast cancer down to 41% of the level in the wild-type cohort, which was not seen for the healthy mutation carrier LCLs ([Figure 5](#fig5){ref-type="fig"}). Comparison of mean P-RPA (and RPA) band intensities failed to detect major differences between the cohorts. Finally, we investigated endogenous protein levels of key factors implicated in pathway choice decisions. Thus, we examined the important regulator of DSB signaling 53BP1, which promotes NHEJ and antagonizes homologous repair, MRE11, the nuclease component of the DSB recognizing and end processing MRE11-RAD50-Nibrin complex as well as the downstream nuclease CtIP, PARP1, which has been implicated in alternative NHEJ, and RAD51 the central recombinase in HR.^[@bib42],\ [@bib46]^ Interestingly, we observed a 2.3-fold increase of 53BP1 protein levels in the cohort of healthy mutation carriers compared with the wild-type cohort that was lost in the *PALB2*-mutated breast cancer patients ([Figure 5](#fig5){ref-type="fig"}). For comparison, none of the other proteins (MRE11, PARP1, RAD51, CtIP) showed quantitative changes. Suggesting posttranslational stabilization of 53BP1 in *PALB2*-mutated healthy individuals versus breast cancer patients, we observed no change and a 53BP1 decrease, respectively, following exposure to the protein biosynthesis inhibitor Cycloheximide ([Supplementary Figure 4a](#sup1){ref-type="supplementary-material"}). Consistent with 53BP1\'s proposed role,^[@bib46]^ we found a statistically significant decrease of NHEJ upon *53BP1* knockdown in *PALB2* mutation carriers with and without breast cancer ([Supplementary Figure 4b](#sup1){ref-type="supplementary-material"}). MMEJ was dependent on 53BP1 only in breast cancer patients. For comparison, inactivation/knockdown of the key factors of HR (RAD51) and SSA (RAD52) caused increased and decreased SSA, respectively, in cells from wild-type *PALB2* control individuals ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Upon RAD52 knockdown, diminished SSA (and MMEJ, also called micro-SSA) was also noticeable in cells from the healthy *PALB2* mutation carrier, but not from the breast cancer patient of the same family. Therefore, RAD52-independent mechanisms promote SSA in *PALB2*-mutated cells from the breast cancer patients.

Discussion
==========

The EMBRACE study demonstrated the dramatic effect of modifier genes on the cancer risk of *BRCA2* mutation carriers.^[@bib47]^ These results underscore the need for comprehensive parameters, which describe the combined breast cancer risk of high-penetrance susceptibility genes in the individual\'s genetic background. In our previous study, we demonstrated an association between distinct DSB repair activities and breast cancer risk.^[@bib40]^ The heterozygous Finnish *PALB2* c.1592delT founder mutation leads on average to a sixfold increase in breast cancer risk.^[@bib9]^ In our study, we elucidated the DSB repair phenotype of female *PALB2* c.1592delT mutation carriers as compared with wild-type individuals.

The heterozygous *PALB2* germline mutation most prominently caused increases in the error-prone activities MMEJ (2- to 10-fold) and even more significantly in SSA/SSA+HR (2- to 11-fold) as determined via analysis of cohorts and comparison of individual carrier LCLs versus wild-type reference. These data indicated a mixed phenotype of *PALB2* mutation carrier cells as compared with heterozygously *BRCA1*-mutated cells, which had correspondingly been characterized by 3- to 16-fold elevated MMEJ and heterozygously *BRCA2*-mutated cells with threefold increased SSA activities.^[@bib36]^ This mixed cellular phenotype reflects the physical interactions of PALB2 connecting BRCA1 and BRCA2.^[@bib19],\ [@bib20],\ [@bib21]^ As previously observed with heterozygously *BRCA1*- and *BRCA2*-mutated cells,^[@bib36]^ HR was not consistently found to be impaired in heterozygously mutated *PALB2* cells. This finding can partially be explained by the fact that HR frequencies were closer to the detection limit, which made HR and a further decrease of this activity more difficult to detect. On the other hand, a fivefold HR decrease was in fact measured in one *PALB2*-mutated cell type ([Table 1](#tbl1){ref-type="table"}). Another explanation could be that alternative HR repair mechanisms engaging RAD52 or involving template switch or break-induced replication, which are not or less sensitive to lack of RAD51 and BRCA2,^[@bib48],\ [@bib49],\ [@bib50]^ became prevalent in *PALB2* mutation carrier cells. Finally, the possibility remains that the *PALB2* (c.1592delT/wt) status is associated with haploinsufficiency regarding the suppression of error-prone DSB repair activities but with haplosufficiency regarding stimulation of RAD51-dependent HR. In agreement with this concept, we monitored normal RAD51 foci kinetics in most of the *PALB2* mutation carrier cell lines. Moreover, the accumulation and decline of DSBs as indicated by 53BP1 foci after irradiation or MMC treatment were similar in wild-type and mutated cell types. A clue to haploinsufficiency regarding the suppression of error-prone repair could be that the truncated *PALB2* c.1592delT gene product is highly unstable. Upon overexpression, truncated PALB2 may also exert a dominant-negative influence via the N-terminal BRCA1-binding site^[@bib21],\ [@bib32]^ as suggested from the observed increase in error-prone DSB repair. BRCA1 via its association with CtIP is involved in the pathway choice, as it promotes DSB end resection and therefore homologous repair rather than classical NHEJ.^[@bib26]^ In normal cells, BRCA1 promotes RAD51-dependent HR via its association with PALB2. Blocking PALB2 but not CtIP interactions will favor RAD51-independent homologous repair like SSA and other unscheduled processes requiring ssDNA overhangs like MMEJ.

Measurements of total NHEJ, encompassing canonical and alternative activities, revealed augmented usage of NHEJ in the majority of *PALB2* mutation carrier cell lines, however, also in several wild-type *PALB2* LCLs. Previous data indicated the involvement of not only MMEJ but also SSA in generating chromosomal rearrangements that can lead to malignancies.^[@bib51]^ Notably, a reduced capacity to reactivate stalled replication forks as well as chromosomal aberrations including complex rearrangements that are mechanistically linked with homologous repair activities have been observed in *PALB2* c.1592delT mutation carriers.^[@bib32]^ Fully error-prone DSB repair activities (MMEJ, SSA) were increased in all studied *PALB2* mutation carrier LCLs except for two from breast cancer patients. One of those two cell lines, namely from the patient undergoing therapy, was particular as it did not match the DSB repair pattern of the other *PALB2*-mutated LCLs (neither increase of NHEJ, MMEJ, SSA and/or SSA+HR but decrease of HR) which might indicate interference of cytostatic treatment with the DSB response. When disregarding this cell line, augmentation of MMEJ and SSA each associated with five out of six of the *PALB2*-mutated LCLs, however, also detected one (MMEJ) and two out of six (SSA), respectively, wild-type *PALB2* LCLs (including BR-0968, [Table 1](#tbl1){ref-type="table"}). Notably, the relative increase detected in the few wild-type LCLs was also less pronounced, namely less than 2-fold for MMEJ and 2- to 5-fold for SSA versus in *PALB2*-mutated cells 2- to 10-fold and 2- to 8-fold, respectively.

When performing cohort analysis, we confirmed the increase of MMEJ and SSA in the *PALB2* c.1592delT mutation carriers. Subgroup analysis further revealed a rise of SSA in the breast cancer patients compared with wild-type controls and of NHEJ in the breast cancer patients compared with the healthy mutation carriers. Considering that *PALB2* is a FA gene,^[@bib13],\ [@bib14]^ our finding on NHEJ is in line with earlier reports demonstrating that FA cells exhibit elevated NHEJ.^[@bib52]^ Hence, mutation carriers with breast cancer more frequently used error-prone DSB repair pathways, which are known to induce genomic instability, and therefore are likely to have accelerated malignancy formation. We propose that additional genetic alterations in this group of *PALB2* mutation carriers exacerbated the HR defect and usage of error-prone DSB repair pathways and thus breast cancer risk.

The principle of synthetic lethality has been pursued in PARP inhibitor trials targeting HR-defective tumors.^[@bib43]^ In line with the proficiency in HR of the heterozygous *PALB2* c.1592delT mutation carriers, we found increased sensitivity to the drug only in two *PALB2* mutation carrier cell lines derived from breast cancer patients. One possibility to explain PARP inhibitor sensitivity in these two but not the other LCLs could be that additional genetic or epigenetic alterations might have exacerbated the defect.

Of interest regarding a potential role of the *PALB2* c.1592delT mutation in the response of breast cancer patients to conventional chemotherapies, we observed increased levels of 53BP1 in healthy *PALB2* c.1592delT mutation carriers but not in breast cancer patients. Together with RIF1 and PTIP, 53BP1 was reported to prevent unscheduled resection of DSBs, particularly in BRCA1-deficient cells.^[@bib46]^ Consistent with a role of 53BP1 in NHEJ,^[@bib46]^ *53BP1* knockdown downregulated NHEJ in both the cohort of *PALB2*-mutated healthy individuals as well as in breast cancer patients. However, 53BP1 was limiting for MMEJ in breast cancer patients in particular. Our results further suggested that RAD52 may contribute to SSA and MMEJ in healthy mutation carriers, while RAD52-independent SSA and MMEJ mechanisms^[@bib53]^ may have a more important role in patients. Altogether, we found differential involvement of DSB repair components in compensatory error-prone DSB repair in healthy mutation carriers and breast cancer patients. Importantly, in triple-negative breast cancer, which is frequently associated with a nonfunctional BRCA1 and FA pathway, 53BP1 was found to be downregulated in a subset of the cases associated with reduced therapeutic responsiveness and probability of survival.^[@bib54],\ [@bib55]^ Therefore, our findings also impact on the design of personalized treatment regimens of breast cancer patients with a *PALB2* c.1592delT mutation.

Functional assays gradually enter the clinic to contribute to the classification of variants of uncertain significance in *BRCA1* and *BRCA2*.^[@bib56],\ [@bib57]^ Our previous work has taken functional analysis one step further demonstrating DSB repair dysregulation directly in immortalized and primary cells derived from individuals with hereditary breast cancer risk.^[@bib36]^ In this study, we observed haploinsufficiency in *PALB2* c.1592delT mutation carriers (without therapy) regarding the suppression of error-prone DSB repair, however, not regarding HR changes, RAD51 filament assembly or PARP inhibitor sensitivity. Thus, mutation carriers exhibited significantly increased MMEJ and SSA activities. This shift in DSB repair pathway usage is particularly detrimental in the context of the aberrant replication phenotype observed previously in the same *PALB2* c.1592delT mutation cohort cells.^[@bib32]^ We consider the replication stress as a source of DSBs in combination with the increased error-prone DSB repair described here sufficient to explain the increase in genetic aberrations including complex chromosomal rearrangements in *PALB2* c.1592delT mutation carrier cells.^[@bib32]^ The difference in DSB repair pathway usage was even more significant in the *PALB2* mutation carriers with breast cancer, underscoring the potential of the functional approach to capture additional risk factors. Intriguingly, in the breast cancer patients, we noticed the loss of 53BP1 accumulation, which has prognostic value in triple-negative breast cancer patients. Combining analysis of error-prone DSB repair activities and of 53BP1 levels may contribute to multifactorial models to predict the pathogenicity of individual risk genes, the individual cancer risk and/or therapeutic responses.

Materials and methods
=====================

LCLs and cell culturing
-----------------------

LCLs originating from seven female Finnish *PALB2* c.1592delT mutation carriers and six wild-type matched controls ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) were provided by the Laboratory of Cancer Genetics and Tumor Biology, University of Oulu, Finland, and described in the study by Nikkilä *et al.*^[@bib32]^ Additional LCLs were HA238 with heterozygously mutated *BRCA2* (provided by Medical University Hannover, Germany), GM13023A with biallelic *BRCA2/FANCD1*-mutation (purchased at Coriell Institute, Camden, NJ, USA), and the control LCL TK6 (provided by Eppendorf University Clinic, Hamburg, Germany), which were all described in the study by Keimling *et al.*^[@bib36]^ LCLs were cultivated in RPMI 1640 medium (Gibco/Invitrogen, Carlsbad, CA, USA) supplemented with 15% fetal bovine serum (Biochrom, Merck Millipore, Darmstadt, Germany) and antibiotics (Penicillin-Streptomycin-Glutamine, Gibco/Invitrogen). Experiments were performed in antibiotic-free media with 1.5% L-glutamine (Gibco/Invitrogen). All LCLs were tested negative for *Mycoplasma* contamination.

DSB repair analysis
-------------------

LCLs were analyzed in sets, whereby the reference LCL BR-0968 was included in all sets. The capacity and quality of DSB repair was analyzed by use of a previously described *EGFP*-based test system.^[@bib39]^ For this purpose, LCLs were electroporated with a plasmid mixture containing 10 μg of one of the DSB repair substrates (EJ5SceGFP, EJ-EGFP, 5\'EGFP/HR-EGFP, HR-EGFP/3\'EGFP, HR-EGFP/5\'EGFP)^[@bib39],\ [@bib58]^ together with 10 μg of the meganuclease expression plasmid pCMV-I-*Sce*I, and 10 μg of the filler plasmid pBS by use of a Gene Pulser with Pulse Controller from Bio-Rad (München, Germany) at 220 V and 1050 μF. To specify transfection efficiencies, wild-type *EGFP* expression plasmid was used instead of pBS in parallel samples each. Fourty-eight hours post transfection, green fluorescent cells containing reconstituted EGFP were quantified by flow cytometry using FACSCalibur (Becton-Dickinson, Heidelberg, Germany). Laser excitation was effected at 488 nm and gated life cells (side scatter/forward scatter dot plot) were detected in the FL1/FL2 channel. The recombination frequency was calculated by green fluorescent cells per life cell count divided by the transfection efficiency per life cell count. In experiments analyzing exogenous PALB2 protein, we added 40 μg of the POZ-PALB2 expression plasmid for HA-tagged wild-type PALB2^[@bib41]^ or of the expression plasmid for the tagged truncated variant encoded by *PALB2* c.1592delT (Origene, Rockville, MD, USA). To silence 53BP1 during DSB repair measurements, we included 40 μg of two specific pRS-based shRNA expression plasmids (Origene) into the mixture, to express RAD51SM pcDNA3.1-Rad51SM, to silence RAD52 pSUPER-RAD52.

Our study followed the guideline by Guidugli *et al.*^[@bib57]^ of assay development for *BRCA2* mutation carriers. Thus, we used an internal reference, replicated each sample, repeated each experiment at least twice, measured the transfection efficiency and prepared plasmids in batches to assure the same DNA quality. During assay optimization, we added further quality criteria to the present study, namely a minimum transfection efficiency for HR (⩾10%), maximum LCL passage numbers (⩽25) and performed the whole study in a blinded manner.

Immunofluorescence microscopic analysis
---------------------------------------

LCLs were exposed to 2 Gy of ionizing radiation (Cs-137, GSR D1, Gamma-Service Medical GmbH, Leipzig, Germany) or treated with MMC (2.6 μ[M]{.smallcaps}; Sigma-Aldrich, Steinheim, Germany) for 45 min, reincubated with fresh medium and harvested at the indicated time points post treatment. After cytospinning (Cytospin3 Centrifuge, Shandon, Bohemia, NY, USA) at 28 × *g* for 5 min on slides covered by poly-L-Lysine (Sigma-Aldrich), cells were, depending on the specific antibody applied, pre-extracted or fixed immediately with 3.7% formaldehyde followed by permeabilization with 0.5% TritionX-100. Five percent Goat Serum (Invitrogen, Karlsruhe, Germany) in phosphate-buffered saline was utilized for blocking. Primary antibodies used were polyclonal antibodies targeting 53BP1 (NB100-304, Novus Biologicals, Littleton, CO, USA) and RAD51 (H-92, Santa Cruz Biotechnology, Heidelberg, Germany); secondary antibody was AlexaFluor555-labeled (Invitrogen). Stained cells were mounted either with Dabco (1,4-Diazabicyclo\[2.2.2\]-octane, Sigma-Aldrich) and Mowiol (MOWIOL^R^ 4--88 Reagent, Calbiochem, Merck Millipore) after staining with DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride, Sigma-Aldrich) or Vectashield containing DAPI (Vector laboratories, Burlingame, CA, USA). Focal accumulation of 53BP1 and RAD51 in the nuclei was analyzed in a time-dependent manner using an Olympus BX51 epifluorescence microscope with × 100 oil immersion objective fitted with cooled charge-coupled device camera (Colorview 12, Olympus, Tokyo, Japan) and Cell\^F imaging software version 2.5 (Olympus Soft Imaging Solutions, Münster, Germany). On each experimental day, 50 nuclei from two independent slides were analyzed. The threshold was maintained throughout one experimental set.

PARP inhibitor sensitivity
--------------------------

To assess the response to the PARP inhibitor 1,5-isoquinolinediol (ENZO, New York, NY, USA), MTT assay was performed as described.^[@bib59]^ One day post seeding, LCLs were treated with different 1,5-isoquinolinediol concentrations from 2 μ[M]{.smallcaps} to 2 m[M]{.smallcaps} 1,5-isoquinolinediol for 6 days.

Western blotting
----------------

LCLs were mock-treated or treated with MMC (2.6 μ[M]{.smallcaps}) for 45 min followed by incubation in fresh media and harvested at the indicated time points. After preparation of the lysates, proteins were electrophoresed by SDS--PAGE and transferred to nitrocellulose or polyvinylidene fluoride membrane. Proteins were detected by the following antibodies recognizing 53BP1 (NB100-304, Novus Biologicals, Cambridge, UK), CtIP (T-16, Santa Cruz Biotechnology, Santa Cruz, CA, USA), MRE11 (NB100-142, M-2; Novus Biologicals), RAD51 (H-92, Santa Cruz Biotechnology), RAD52 (5H9, Abcam, Cambridge, UK), RPA (Ab-2, Calbiochem, Darmstadt, Germany), phospho-RPA (P-RPA; S33, Bethyl Laboratories, Montgomery, TX, USA), PARP1 (\#9542, Cell Signalling, Danvers, MA, USA), γH2AX (Clone JBW 301 Ser139, Millipore, Billerica, MA, USA), peroxidase-conjugated HA-tag (3F10, Roche, Mannheim, Germany) and α-Tubulin (ab7291, Abcam). Secondary antibodies were peroxidase-conjugated goat anti-mouse (Thermo Scientific, Waltham, MA, USA), anti-rabbit and anti-goat IgG (Rockland, Gilbertsville, PA, USA). Bands were visualized with Clarity Western ECL Substrate (Bio-Rad Laboratories) by ChemiDoc MP Imaging System and quantified using Image Lab 4.1 (Bio-Rad Laboratories).

Statistical evaluation
----------------------

The statistical significances of differences for set-wise DSB repair measurements, foci analysis and Spearman correlation were determined by the software GraphPad Prism 5.04 (GraphPad, San Diego, CA, USA). Once statistical significance was established for a data set by Kruskal--Wallis test, non-parametric Mann--Whitney test for unpaired samples was applied. GraphPad Prism 5.04 software was further used to generate cell viability curves, calculate IC50 values and statistical significances of the differences between the IC50 values by Extra sum-of-squares F-test of Log IC50. Cohort analyses of DSB repair pathway usage and DNA damage signals were performed using IBM SPSS Statistics Software package version 21. DSB repair pathway usage was analyzed using a general linear mixed model with mutation/health status as fixed factor and date of experiment as random factor. DNA damage signals were analyzed using general linear models with mutation/health status and treatment group (untreated control, 0 or 1 h post treatment, 6 h post treatment) as fixed factors. *Post hoc* tests were adjusted for multiple comparisons using Bonferroni correction. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001; \*\*\*\**P*\<0.0001.
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![Assay for comparison of DSB repair pathway usage in individuals with wild-type and heterozygously mutated *PALB2*. (**a**) Assay principle for the analysis of DSB repair pathways in LCLs.^[@bib39]^ Representatively shown is the construct enabling HR between a mutated *EGFP*-acceptor sequence with an I-*Sce*I recognition site and a donor sequence representing truncated *EGFP*. A plasmid mixture, containing the DSB repair substrate HR-EGFP/5\'EGFP, I-*Sce*I-meganuclease expression plasmid (pCMV-I-*Sce*I), and either filler plasmid pBS or wild-type *EGFP* expression plasmid were introduced into the LCLs by electroporation followed by cultivation for 48 h. DSB repair was triggered by I-*Sce*I-mediated DSB formation followed by the restoration of *EGFP* and appearance of green fluorescent cells which were analyzed flow cytometrically. As proof-of-principle, BR-0968 and BR-0967 cells with wild-type and heterozygously mutated *PALB2* were transfected according to the protocol and cells harvested 24 h later. Expression of the HA-I-*Sce*I fusion protein was verified by immunoblotting with antibody directed against the HA-tag. Transfection efficiencies were determined for each sample and used to individually normalize DSB repair frequencies thereby excluding potential frequency changes related to transfection, transcription, translation, proliferation and lethality. (**b**) Constructs for specific DSB repair analysis. Constructs for the assessment of different DSB repair pathways are shown: NHEJ (EJ5SceGFP), MMEJ (EJ-EGFP), SSA (5\'EGFP/HR-EGFP), SSA+HR (HR-EGFP/3\'EGFP) and HR (HR-EGFP/5\'EGFP). The NHEJ substrate contains two I-*Sce*I recognition sites. Mutated *EGFP* genes, light gray boxes; deleted *EGFP* sequence, cross; I-*Sce*I recognition site, white triangle; microhomologies, gray triangles; promoter sequence, gray box; spacer sequence, black box.](onc2015448f1){#fig1}

![Cohort analysis of DSB repair pathway usage in wild-type and heterozygously *PALB2*-mutated individuals with and without breast cancer. (**a**) DSB repair as a function of the endogenous PALB2 status. LCLs from six wild-type *PALB2* individuals (white columns) and six *PALB2* c.1592delT mutation carriers (dark gray columns, left panel), among those two from healthy individuals (light gray columns, right panel) and four from breast cancer patients (dark gray columns, right panel), were transfected with reporter constructs for analysis of NHEJ, MMEJ, SSA and SSA+HR and repair frequencies determined as described in the legend to [Figure 1](#fig1){ref-type="fig"}. Frequencies relative to the reference cell line BR-0968 with wild-type *PALB2* (100%) were determined in 6--36 measurements (average of absolute values corresponding to 100%: NHEJ: 2.9 × 10^−3^; MMEJ: 5.2 × 10^−4^; SSA: 2.3 × 10^−3^; SSA+HR: 2.4 × 10^−3^). Data are shown in box plots including mean value (cross) and median (line), 95% confidence interval (CI). Statistical analyses with SPSS were performed using general linear mixed models with mutation status (wild-type or *PALB2*-mutated, left panel) or mutation and health status (wild-type, *PALB2*-mutated and healthy, *PALB2*-mutated and breast cancer; right panel) as fixed factor and date of the experiment as random factor; asterisks indicate a statistically significant difference. (**b**) DSB repair as a function of the exogenous PALB2 status. LCLs from five to six wild-type *PALB2* individuals (except BR-1023 for wild-type PALB2 expression, white columns) and all six *PALB2* c.1592delT mutation carriers not undergoing therapy (gray columns) were transfected with the plasmid mixture for analysis of SSA+HR plus expression plasmid for wild-type PALB2 (wtPALB2), the mutated variant (mutPALB2) or empty vector. DSB repair frequencies were determined as described in (**a**). Mean DSB repair frequencies of each cell line transfected with the empty vector were set to 100%. Data are shown in box plots including mean value (cross) and median (line), 95% CI. Statistically significant differences were calculated by SPSS using Mann--Whitney U test. Asterisks indicate a statistically significant difference. Expression of exogenous PALB2 proteins in LCLs was verified by immunoblotting of lysates with antibody directed against the protein-tag (representatively shown for one wild-type control and one mutation carrier LCL expressing HA-tagged wild-type PALB2; an arrow marks the band specific for HA-tagged PALB2). α-Tubulin was used as the loading control.](onc2015448f2){#fig2}

![Cohort analysis of PARP inhibitor sensitivities. To determine the cell viability after treatment with the PARP inhibitor 1,5-isoquinolinediol (IQD), increasing IQD concentrations (2 μ[M]{.smallcaps}-2 m[M]{.smallcaps}) were applied. Media were replaced with fresh media including the corresponding IQD concentrations every second day. Cell viability was measured using MTT assay. Mean IC50 values (μM) were determined from 4 to 18 survival curves per LCL and statistical significances calculated using F-test of Log IC50 with software GraphPad Prism version 5.04. The mean IC50 values were visualized as columns in three cohorts, encompassing six LCLs with wild-type *PALB2* (white columns), two LCLs derived from healthy *PALB2* mutation carriers (light gray columns), and four LCLs from *PALB2* mutation carriers with breast cancer (dark gray columns). Bars show s.d. (*n*=2--6).](onc2015448f3){#fig3}

![Cohort analysis of DNA damage signals based on immunofluorescence microscopy. DNA damage was induced by ionizing radiation (IR, 2 Gy) (**a**, **b**) or with MMC (2.6 μ[M]{.smallcaps}, 45 min) (**c**) followed by reincubation in fresh medium. Focal accumulation of the damage marker 53BP1 (**a**, **c**) or the recombinase RAD51 (**b**) in the nuclei were analyzed at the indicated time points post treatment by immunofluorescence microscopy (IR: 1 h (0.5--1.0 h), 6 h; MMC: 0 h, 6 h). Immunolabeled foci from two slides and two independent experiments each were scored by automated quantification of 25 nuclei for each slide. Maximum mean scores for the wild-type LCL BR-0968 were set to 100% in each experiment and relative percentages calculated for each single value (corresponding to one slide). Data are shown in box plots (*n*=8--40) including mean value (cross) and median (line), 95% confidence interval. Statistical analyses with SPSS were performed using general linear models with mutation and health status (wild-type, *PALB2*-mutated and healthy, *PALB2*-mutated and breast cancer) and treatment group (untreated control, 0 or 1 h post treatment, 6 h post treatment) as fixed factor. Wild-type *PALB2*, white columns; healthy *PALB2*-mutated carriers, light gray columns; *PALB2*-mutated breast cancer patients, dark gray columns. (**a**) 53BP1 foci analysis after IR. (**b**) RAD51 foci analysis after IR. (**c**) 53BP1 foci analysis after MMC treatment.](onc2015448f4){#fig4}

![Cohort analysis of DSB repair protein levels. Endogenous levels of DSB repair proteins in LCLs from twelve Finnish donors were visualized by immunoblotting of lysates containing 50 μg protein per sample with antibodies directed against γH2AX, P-RPA, RPA, 53BP1, MRE11, PARP1, RAD51and CtIP. α-Tubulin was used as loading control. Samples were collected from untreated LCLs (basal level), immediately (0 h) or 6 h after treatment with MMC (2.6 μ[M]{.smallcaps}, 45 min). Two independent immunoblotting experiments were performed for each cell line. Band intensities were quantified and individually corrected with the loading control. Arrows indicate quantified bands in case of several bands. The wild-type *PALB2* LCL BR-0968 was used as reference on each immunoblot and set to 100%. Columns represent the mean relative changes (versus BR-0968) of protein levels per tested cell line from three cohorts, namely six LCLs with wild-type *PALB2* (white columns), two LCLs derived from healthy *PALB2* mutation carriers (light gray columns) and four LCLs from *PALB2* mutation carriers with breast cancer (dark gray columns). Bars show s.d. (*n*=2--6). brca+ther, breast cancer patient undergoing cytostatic therapy.](onc2015448f5){#fig5}

###### DSB repair frequency changes in LCLs from *PALB2* mutation carriers and wild-type controls

  *Cell line*   *PALB2 genotype*   *Health status*   *DSB repair frequency change: mean tested LCL versus mean wild-type control*[a](#t1-fn2){ref-type="fn"} (P*-value)*[b](#t1-fn3){ref-type="fn"}                                                    
  ------------- ------------------ ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------ -------------- ---------------- ---------------- -------------------------------
  BR-0954       c.1592delT/wt      Healthy           1.5 (0.0260)                                                                                                                                     1.8 (0.0028)   1.6 (0.0003)     1.8 (0.0078)                   ns
  BR-0967                                            ns[c](#t1-fn4){ref-type="fn"}                                                                                                                    3.4 (0.0022)   4.0 (0.0022)     3.5 (0.0022)      nd[d](#t1-fn5){ref-type="fn"}
  BR-0724                          brca              2.7 (0.0022)                                                                                                                                     ns             0.6 (0.0043)     ns                             nd
  BR-0736                                            2.7 (0.0022)                                                                                                                                     9.6 (0.0022)   7.9 (0.0022)     10.9 (0.0022)                  nd
  BR-0737                                            3.4 (0.0022)                                                                                                                                     2.4 (0.0142)   1.8 (\<0.0001)   2.0 (0.0019)                   ns
  BR-0760                                            2.1 (0.0087)                                                                                                                                     1.9 (0.0188)   3.5 (\<0.0001)   3.8 (\<0.0001)                 ns
  BR-0970                          brca+ therapy     ns                                                                                                                                               ns             ns               0.7 (0.0028)              0.2 (0.0078)
  BR-0778       Wild-type          Healthy           4.1 (0.0022)                                                                                                                                     1.4 (0.0260)   ns               2.0 (0.0043)                   ns
  BR-0781                                            1.9 (0.0043)                                                                                                                                     ns             ns               ns                             ns
  BR-1016                                            ns                                                                                                                                               ns             ns               ns                             ns
  BR-1017                                            1.9 (0.0022)                                                                                                                                     ns             5.3 (0.0022)     7.2 (0.0022)                   nd
  BR-1023                                            2.8 (0.0022)                                                                                                                                     ns             2.1 (0.0022)     1.8 (0.0022)                   nd

Abbreviations: brca, breast cancer patient; brca+therapy, breast cancer patient undergoing cytostatic therapy; DSB, double-strand break; HR, homologous recombination; LCLs, lymphoblastoid cell lines; MMEJ, microhomology-mediated end-joining; NHEJ, non-homologous end-joining; SSA, single-strand annealing. LCLs were subjected to pathway-specific DSB repair measurements as described in the legend to [Figure 1](#fig1){ref-type="fig"}. Each *PALB2*-mutated LCL was analyzed parallel to the wild-type reference LCL BR-0968 and mean frequencies were set to 100%. Mean frequencies from at least six biological replicates were determined (replicate numbers for NHEJ/MMEJ/SSA/SSA+HR/HR: BR-0954 6/9/9/9/6, BR-0967 6/6/6/6/6, BR-0724 6/6/6/6/6, BR-0736 6/6/6/6/6, BR-0737 6/9/9/9/9, BR-0760 6/9/9/9/9, BR-0970 6/9/9/9/9, BR-0778 6/6/6/6/6, BR-0781 6/6/6/6/6, BR-1016 6/9/9/9/6, BR-1017 6/6/6/6/6, BR-1023 6/6/6/6/6, and reference BR-0968 18/36/33/36/24). Relative frequency changes between tested and reference LCLs were calculated. Statistically significant differences were calculated by Mann--Whitney test for unpaired samples. Note that HR measurements were not calculated for several LCLs (nd) because of transfection efficiencies \<10%, so that HR frequencies were close to the detection limit.

DSB repair frequency changes (x-fold) for tested LCLs in relation to wild-type control BR-0968 analyzed in parallel (*n*=6--9).

*P*-values were calculated by Mann--Whitney test for unpaired samples.

ns, statistically non-significant (*P*\>0.05).

nd, not determined; note that HR measurements were not calculated for several LCLs (nd) because of transfection efficiencies \<10%, so that HR frequencies were close to the detection limit.

###### PARP inhibitor sensitivities of LCLs with mutations in *BRCA2* or *PALB2* versus wild-type

  *Cell line*   *Genotype*                   *Health status*   *IC50*[a](#t2-fn2){ref-type="fn"}    P*-value*[b](#t2-fn3){ref-type="fn"}
  ------------- ---------------------------- ----------------- ----------------------------------- --------------------------------------
  TK6           Wild-type                    Healthy           76                                                    −
  HA238         *BRCA2* (c.5946delCT/wt)     brca              45                                                  0.0464
  GM13023A      Biallelic *BRCA2* mutation   Fanconi anemia    12                                                 \<0.0001
  BR-0968       Wild-type                    Healthy           39                                                     
  BR-0778                                                      23                                                  0.2130
  BR-0781                                                      57                                                  0.0556
  BR-1016                                                      47                                                  0.4858
  BR-1017                                                      26                                                  0.5245
  BR-1023                                                      38                                                  0.7369
  BR-0954       *PALB2* (c.1592delT/wt)      Healthy           41                                                  0.6937
  BR-0967                                                      38                                                  0.6241
  BR-0724                                    brca              45                                                  0.7500
  BR-0736                                                      36                                                  0.8263
  BR-0737                                                      24                                                  0.4956
  BR-0760                                                      16                                                  0.0469
  BR-0970                                    brca+therapy      6                                                   0.0432

Abbreviations: brca, breast cancer patient; brca+therapy, breast cancer patient undergoing cytostatic therapy; LCLs, lymphoblastoid cell lines. LCLs were treated with increasing concentrations of 1,5-isoquinolinediol (IQD; 2 μ[M]{.smallcaps}--2 m[M]{.smallcaps}). Cell viability was assessed using MTT assay as described in the legend to [Figure 3](#fig3){ref-type="fig"}. IC50 values (μM) were determined from 4 to 18 survival curves and statistical significance calculated using F-test of Log IC50 with software GraphPad Prism version 5.04 (numbers of survival curves: BR-0954 6, BR-0967 4, BR-0724 6, BR-0736 6, BR-0737 8, BR-0760 6, BR-0970 4, BR-0778 10, BR-0781 10, BR-1016 6, BR-1017 6, BR-1023 4 and reference BR-0968 18)). *P*-values of differences between IC50 values determined in parallel were calculated for *BRCA2*-mutated LCLs versus for wild-type LCL TK6 and for *PALB2*-mutated LCLs versus for wild-type reference LCL BR-0968.

Sensitivity to PARP inhibitor IQD treatment (exposure to 2 μ[M]{.smallcaps}--2 m[M]{.smallcaps} for 6 days) was assessed by calculating IC50 values (μM) from 4 to 18 survival curves by use of the software GraphPad Prism version 5.04.

*P*-values of differences between IC50 values determined in parallel were calculated for *BRCA2*-mutated LCLs versus for wild-type LCL TK6 and for *PALB2*-mutated LCLs versus for wild-type reference LCL BR-0968.
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